This meta-epidemiological assessment evaluates the reliability of the Global Burden of Disease risk factor estimates for mortality and disability-adjusted life-years. from JAMA Health Forum New Online https://ift.tt/Aip9r2O

This cross-sectional study quantifies federal lobbying expenditures by the hospital industry in 2024 and compares variations in lobbying expenditures by hospital ownership status. from JAMA Health Forum New Online https://ift.tt/iBlTKuH

This Viewpoint discusses the Make America Healthy Again Commission’s “Make Our Children Healthy Again” report, which implicates the food industry for its role in the chronic disease epidemic. from JAMA Health Forum New Online https://ift.tt/HWtRPKT

This JAMA Forum discusses changes under the Trump administration to the vaccination schedule, oversight of vaccine safety, the National Vaccine Injury Compensation Program, and the Vaccines for Children program. from JAMA Health Forum New Online https://ift.tt/9lXbtiy

This difference-in-differences analysis evaluates the association of the Inflation Reduction Act’s 2024 prescription drug provisions with cost-related medication nonadherence as well as health care–related financial strain. from JAMA Internal Medicine Online First https://ift.tt/4WKJmlU

This essay discusses the author’s reflection on their first night on call as a postgraduate year 1 resident. from JAMA Internal Medicine Online First https://ift.tt/BFyqGx3

This Review summarizes the current evidence on the effects of cannabis on commonly encountered mental health conditions and provides clinicians with basic information about cannabis pharmacology and biology. from JAMA Internal Medicine Online First https://ift.tt/mhskRW3

This Viewpoing describes a framework for the Wasteful and Inappropriate Service Reduction model to promote appropriate and efficient prior authorization determinations in Medicare. from JAMA Internal Medicine Online First https://ift.tt/TUjHF5V

This Viewpoint discusses current regulatory frameworks governing the use of generative artificial intelligence (AI) in health care and proposes an alternative oversight system. from JAMA Health Forum New Online https://ift.tt/zTSYiJD

This JAMA Forum discusses health coverage implications for Affordable Care Act Marketplace plans and Medicaid after passage of the budget reconciliation package in 2025 and changes in the rates of uninsurance. from JAMA Health Forum New Online https://ift.tt/oaqz1HT

This systematic review and meta-analysis quantifies the heterogeneity of treatment effects of glucagon-like peptide-1 receptor agonists, including semaglutide, liraglutide, exenatide, lixisenatide, and dulaglutide. from JAMA Internal Medicine Online First https://ift.tt/T24XD9A